
Claims

1. (R)-Compound 1 for use in the treatment of hypertension or primary aldosteronism in a human having a mean seated blood pressure of ≥130/80 mmHg, comprising administering 0.1 to 10 mg/day of (R)-Compound 1 to the human:



(R)-Compound 1.

2. (R)-Compound 1 for use of claim 1, wherein the human is on a stable background hypertensive regimen prior to the administration of the (R)-Compound 1.

3. (R)-Compound 1 for use of claim 2, wherein the stable background hypertensive regimen comprises ≥3 antihypertensive agents.

4. (R)-Compound 1 for use of claim 3, wherein one of the antihypertensive agents is a diuretic.

5. (R)-Compound 1 for use of any one of the preceding claims, wherein the administration of the (R)-Compound 1 results in a mean decrease from baseline in seated systolic blood pressure (SBP) after 4 weeks of treatment.

6. (R)-Compound 1 for use of any one of the preceding claims, wherein the administration of the (R)-Compound 1 results in a mean decrease from baseline in seated systolic blood pressure (SBP) after 12 weeks of treatment.

7. (R)-Compound 1 for use of any one of the preceding claims, wherein the administration of the (R)-Compound 1 results in a mean decrease in baseline in seated diastolic blood pressure (DBP) after 4 weeks of treatment.

8. (R)-Compound 1 for use of any one of the preceding claims, wherein the administration of the (R)-Compound 1 results in a mean decrease in baseline in seated diastolic blood pressure (DBP) after 12 weeks of treatment.

9. (R)-Compound 1 for use of any one of the preceding claims, wherein the administration of the (R)-Compound 1 results in a seated blood pressure (BP) of <130/80 mmHg after 4 weeks of treatment.

10. (R)-Compound 1 for use of any one of the preceding claims, wherein the administration of the (R)-Compound 1 results in a seated blood pressure (BP) of <130/80 mmHg after 12 weeks of treatment.

11. (R)-Compound 1 for use of any one of claims 1 to 10, comprising administering about 1 mg/day of (R)-Compound 1 to the human.

12. (R)-Compound 1 for use of any one of claims 1 to 10, comprising administering about 2 mg/day of (R)-Compound 1 to the human.

13. (R)-Compound 1 for use of any one of the preceding claims, wherein the amount of (R)-Compound 1 is administered to the human in a single dose.


14. (R)-Compound 1 for use of any one of the preceding claims, wherein the administration of the (R)-Compound 1 does not result in a clinically significant adverse event in the human.

15. (R)-Compound 1 for use of any one of the preceding claims, wherein the human is at least 18 years of age.

16. (R)-Compound 1 for use of any one of the preceding claims, wherein hypertension is treated.

17. (R)-Compound 1 for use of any one of the preceding claims, wherein primary aldosteronism is treated.

18. Use of (R)-Compound 1 in the manufacture of a medicament for the treatment of hypertension or primary aldosteronism in a human having a mean seated blood pressure of ≥130/80 mmHg, comprising administering 0.1 to 10 mg/day of (R)-Compound 1 to the human:



(R)-Compound 1.

19. A pharmaceutical composition comprising about 0.1 to about 10 mg of (R)-Compound 1 and a pharmaceutically acceptable excipient.

20. The pharmaceutical composition of claim 19 comprising about 1 mg of (R)-Compound 1 and a pharmaceutically acceptable excipient.

21. The pharmaceutical composition of claim 19 comprising about 2 mg of (R)-Compound 1 and a pharmaceutically acceptable excipient.